Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$106.42 /

-1.35 (-1.25%)

, AYLA

Ayala Pharmaceuticals

$12.00 /

-0.31 (-2.52%)

04:55
09/21/21
09/21
04:55
09/21/21
04:55

European Society for Medical Oncology to hold a virtual meeting

ESMO 2021 Virtual Congress will be held on September 16-21. Webcast Link

ABBV

AbbVie

$106.42 /

-1.35 (-1.25%)

AYLA

Ayala Pharmaceuticals

$12.00 /

-0.31 (-2.52%)

DCPH

Deciphera

$32.28 /

-0.8 (-2.42%)

GMAB

Genmab

$42.88 /

-0.16 (-0.37%)

LPTX

Leap Therapeutics

$2.78 /

+0.125 (+4.72%)

ORIC

Oric Pharmaceuticals

$24.54 /

-0.67 (-2.66%)

SYNH

Syneos Health

$93.51 /

-0.83 (-0.88%)

BGNE

BeiGene

$398.49 /

-5.03 (-1.25%)

BMY

Bristol-Myers

$60.50 /

-0.82 (-1.34%)

BYSI

BeyondSpring

$15.37 /

-7.63 (-33.17%)

CALA

Calithera Biosciences

$2.18 /

-0.07 (-3.11%)

GILD

Gilead

$70.97 /

-0.64 (-0.89%)

GH

Guardant Health

$129.18 /

-2.57 (-1.95%)

LLY

Eli Lilly

$231.74 /

+1.57 (+0.68%)

IPSEY

Ipsen

$24.03 /

+0.105 (+0.44%)

EXAS

Exact Sciences

$105.28 /

-2.97 (-2.74%)

IDYA

Ideaya Biosciences

$26.22 /

-0.68 (-2.53%)

GSK

GlaxoSmithKline

$38.84 /

-0.1 (-0.26%)

RHHBY

Roche

$45.57 /

-0.5 (-1.09%)

REGN

Regeneron

$641.33 /

-10.43 (-1.60%)

PFE

Pfizer

$44.22 /

+0.325 (+0.74%)

TAK

Takeda Pharmaceutical

$17.07 /

-0.095 (-0.55%)

TMO

Thermo Fisher

$589.96 /

-6.64 (-1.11%)

TCRR

TCR2 Therapeutics

$9.39 /

-0.61 (-6.10%)

VERU

Veru

$8.45 /

-0.48 (-5.38%)

VBLT

VBL Therapeutics

$2.23 /

-0.085 (-3.67%)

VTRS

Viatris

$13.33 /

-0.24 (-1.77%)

NVS

Novartis

$82.81 /

-0.68 (-0.81%)

  • 21

    Sep

  • 24

    Sep

  • 27

    Sep

  • 28

    Sep

  • 30

    Sep

  • 07

    Oct

  • 07

    Oct

  • 10

    Oct

  • 18

    Oct

  • 20

    Oct

  • 21

    Oct

  • 22

    Oct

  • 26

    Oct

  • 27

    Oct

  • 08

    Nov

  • 30

    Nov

  • 01

    Dec

  • 29

    Dec

  • 28

    Jan

  • 06

    May

  • 07

    Oct

  • 13

    Nov

  • 19

    Nov

  • 02

    Dec

  • 02

    Dec

  • 20

    Jan

  • 18

    Feb

  • 01

    Mar

  • 09

    Apr

  • 04

    May

  • 03

    Jun

  • 08

    Jul

ABBV AbbVie
$106.42 /

-1.35 (-1.25%)

09/20/21 Citi
Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
09/14/21 Barclays
Regenxbio price target raised to $82 from $79 at Barclays
09/13/21 Chardan
Regenxbio pact with AbbVie accelerates RGX-314 'value capture,' says Chardan
09/08/21 JPMorgan
AbbVie offers 'best risk/reward story in the group,' says JPMorgan
AYLA Ayala Pharmaceuticals
$12.00 /

-0.31 (-2.52%)

07/13/21 Ladenburg
Ayala Pharmaceuticals initiated with Buy, $29 target at Ladenburg
07/13/21 Ladenburg
Ayala Pharmaceuticals initiated with a Buy at Ladenburg
12/07/20
Fly Intel: Top five analyst initiations
12/07/20 Roth Capital
Ayala Pharmaceuticals initiated with a Buy at Roth Capital
DCPH Deciphera
$32.28 /

-0.8 (-2.42%)

08/04/21 H.C. Wainwright
Deciphera price target lowered to $70 from $75 at H.C. Wainwright
05/05/21 Barclays
Deciphera price target lowered to $65 from $70 at Barclays
05/05/21 H.C. Wainwright
Deciphera price target lowered to $75 from $80 at H.C. Wainwright
05/05/21 Piper Sandler
Deciphera price target lowered to $60 from $75 at Piper Sandler
GMAB Genmab
$42.88 /

-0.16 (-0.37%)

09/16/21
Fly Intel: Top five analyst downgrades
09/16/21 Jefferies
Genmab downgraded to Hold from Buy at Jefferies
09/07/21
Fly Intel: Top five analyst downgrades
09/07/21 Morgan Stanley
Morgan Stanley cuts Genmab to Underweight amid high investor expectations
LPTX Leap Therapeutics
$2.78 /

+0.125 (+4.72%)

09/19/21 Piper Sandler
Piper Sandler keeps Overweight on Leap Therapeutics, ups target to $5
09/16/21 Piper Sandler
Leap data show 'very favorable early signal,' says Piper Sandler
09/13/21 Raymond James
Leap Therapeutics price target raised to $4 from $3 at Raymond James
09/13/21 Piper Sandler
Leap combo sees 'strong' early response rate, says Piper Sandler
ORIC Oric Pharmaceuticals
$24.54 /

-0.67 (-2.66%)

07/06/21 Citi
Oric Pharmaceuticals upgraded to Buy after tumor data at Citi
07/06/21 Citi
Oric Pharmaceuticals upgraded to Buy from Neutral at Citi
03/25/21 H.C. Wainwright
Oric Pharmaceuticals price target raised to $54 from $52 at H.C. Wainwright
01/25/21 Citi
Oric Pharmaceuticals downgraded to Neutral from Buy at Citi
SYNH Syneos Health
$93.51 /

-0.83 (-0.88%)

08/04/21 Credit Suisse
Syneos Health assumed with an Outperform at Credit Suisse
07/13/21 Barclays
Syneos Health price target raised to $102 from $90 at Barclays
06/02/21 Truist
Syneos Health price target raised to $104 from $88 at Truist
04/30/21 Mizuho
Syneos Health price target raised to $90 from $82 at Mizuho
BGNE BeiGene
$398.49 /

-5.03 (-1.25%)

06/14/21 SVB Leerink
BeiGene price target raised to $417 from $388 at SVB Leerink
03/16/21 HSBC
BeiGene price target raised to $385 from $296 at HSBC
03/08/21 China Renaissance
BeiGene initiated with a Buy at China Renaissance
03/04/21 Goldman Sachs
Five Prime acquisition 'a strategic positive' for Amgen, says Goldman Sachs
BMY Bristol-Myers
$60.50 /

-0.82 (-1.34%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
07/27/21 Mizuho
Bristol-Myers deal a positive signal about BridgeBio's BBP-398, says Mizuho
07/26/21 Truist
Bristol-Myers assumed with a Buy at Truist
BYSI BeyondSpring
$15.37 /

-7.63 (-33.17%)

09/20/21 H.C. Wainwright
BeyondSpring price target lowered to $65 from $100 at H.C. Wainwright
09/08/21 Baird
BeyondSpring initiated with an Outperform at Baird
08/04/21 Evercore ISI
BeyondSpring price target raised to $95 from $30 at Evercore ISI
08/04/21 William Blair
BeyondSpring may have new standard of care in lung cancer, says William Blair
CALA Calithera Biosciences
$2.18 /

-0.07 (-3.11%)

01/05/21 SVB Leerink
Calithera Biosciences downgraded to Market Perform at SVB Leerink
01/05/21 SVB Leerink
Calithera Biosciences downgraded to Market Perform from Outperform at SVB Leerink
01/05/21 Citi
Calithera Biosciences price target lowered to $5 from $10 at Citi
01/05/21 H.C. Wainwright
Calithera Biosciences price target lowered to $4 from $9.50 at H.C. Wainwright
GILD Gilead
$70.97 /

-0.64 (-0.89%)

07/30/21 BMO Capital
Gilead price target raised to $72 from $67 at BMO Capital
07/30/21 RBC Capital
Gilead price target raised to $84 from $81 at RBC Capital
06/29/21 Jefferies
Gilead data should move Yescarta up to second line in DLBCL, says Jefferies
GH Guardant Health
$129.18 /

-2.57 (-1.95%)

08/09/21 Canaccord
Guardant Health price target lowered to $180 from $195 at Canaccord
06/21/21 Wells Fargo
Guardant Health price target raised to $160 from $145 at Wells Fargo
06/15/21
Fly Intel: Top five analyst initiations
06/15/21 Raymond James
Guardant Health initiated with a Market Perform at Raymond James
LLY Eli Lilly
$231.74 /

+1.57 (+0.68%)

09/02/21 SVB Leerink
AbbVie price target lowered to $142 from $148 at SVB Leerink
08/30/21 Cowen
Eli Lilly price target raised to $300 from $250 at Cowen
08/30/21 Citi
Lexicon price target raised to $20 from $13 at Citi
IPSEY Ipsen
$24.03 /

+0.105 (+0.44%)

08/16/21 Morgan Stanley
Ipsen price target lowered to EUR 88 from EUR 92 at Morgan Stanley
08/03/21 Morgan Stanley
Ipsen price target raised to EUR 92 from EUR 85 at Morgan Stanley
08/02/21 Societe Generale
Ipsen price target raised to EUR 101 from EUR 90 at Societe Generale
07/30/21 Credit Suisse
Ipsen price target raised to EUR 90 from EUR 75 at Credit Suisse
EXAS Exact Sciences
$105.28 /

-2.97 (-2.74%)

09/16/21 Canaccord
Exact Sciences salesforce expansion a net positive, says Canaccord
09/15/21 Raymond James
Exact Sciences' 'opportunistic' hires should boost sales, says Raymond James
09/15/21 Canaccord
Exact Sciences progress in MRD space a positive, says Canaccord
09/01/21 Baird
UnitedHealth update to CRC screening coverage not a surprise, says Baird
IDYA Ideaya Biosciences
$26.22 /

-0.68 (-2.53%)

06/03/21 Baird
Ideaya Biosciences assumed with an Outperform at Baird
04/22/21 Roth Capital
Ideaya Biosciences price target raised to $38 from $31 at Roth Capital
04/19/21 H.C. Wainwright
Ideaya Biosciences price target raised to $35 from $29 at H.C. Wainwright
04/16/21 Roth Capital
Ideaya Biosciences price target raised to $31 from $23 at Roth Capital
GSK GlaxoSmithKline
$38.84 /

-0.1 (-0.26%)

09/20/21 UBS
GlaxoSmithKline price target lowered to 1,460 GBp from 1,540 GBp at UBS
08/26/21 UBS
GlaxoSmithKline price target raised to 1,540 GBp from 1,485 GBp at UBS
08/20/21 JPMorgan
GlaxoSmithKline price target raised to 1,500 GBp from 1,300 GBp at JPMorgan
RHHBY Roche
$45.57 /

-0.5 (-1.09%)

09/07/21 UBS
Roche price target raised to CHF 350 from CHF 345 at UBS
08/02/21 JPMorgan
Roche price target raised to CHF 360 from CHF 310 at JPMorgan
REGN Regeneron
$641.33 /

-10.43 (-1.60%)

09/15/21 Cantor Fitzgerald
Regeneron price target raised to $700 from $670 at Cantor Fitzgerald
09/15/21 H.C. Wainwright
Regeneron price target raised to $831 from $787 at H.C. Wainwright
09/15/21 Piper Sandler
Regeneron price target raised to $690 from $675 at Piper Sandler
09/09/21
Fly Intel: Top five analyst initiations
PFE Pfizer
$44.22 /

+0.325 (+0.74%)

09/17/21 Evercore ISI
Evercore ISI doesn't think FDA panel will recommend COVID-19 boosters
09/16/21 BofA
Moderna boosters already reflected in 'bullish' consensus, says BofA
TAK Takeda Pharmaceutical
$17.07 /

-0.095 (-0.55%)

09/20/21 Oppenheimer
Denali Therapeutics initiated with an Outperform at Oppenheimer
08/03/21 Piper Sandler
Arcturus strength attributable to large pharma's interest in mRNA, says Piper
04/27/21 Chardan
LogicBio collaborations may signal recognition of platforms, says Chardan
04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral on R&D investments at JPMorgan
TMO Thermo Fisher
$589.96 /

-6.64 (-1.11%)

09/20/21 SVB Leerink
Thermo Fisher price target raised to $675 from $600 at SVB Leerink
09/20/21 JPMorgan
Thermo Fisher price target raised to $700 from $600 at JPMorgan
09/20/21 KeyBanc
Thermo Fisher price target raised to $710 from $555 at KeyBanc
09/20/21 Citi
Thermo Fisher price target raised to $620 from $535 at Citi
TCRR TCR2 Therapeutics
$9.39 /

-0.61 (-6.10%)

09/20/21 Truist
TCR2 Therapeutics price target lowered to $29 from $40 at Truist
09/20/21 H.C. Wainwright
TCR2 Therapeutics price target lowered to $25 from $37 at H.C. Wainwright
09/17/21 Wedbush
TCR2 Therapeutics downgraded to Neutral from Outperform at Wedbush
08/06/21 BMO Capital
TCR2 Therapeutics price target lowered to $44 from $53 at BMO Capital
VERU Veru
$8.45 /

-0.48 (-5.38%)

04/13/21 Jefferies
Veru initiated with a Buy at Jefferies
02/11/21 Oppenheimer
Veru price target raised to $24 from $19 at Oppenheimer
02/11/21 H.C. Wainwright
Veru price target raised to $22 from $17 at H.C. Wainwright
02/09/21 H.C. Wainwright
Veru price target raised to $17 from $12 at H.C. Wainwright
VBLT VBL Therapeutics
$2.23 /

-0.085 (-3.67%)

08/30/21 Roth Capital
Roth bullish on VBL Therapeutics as U.S. Phase 3 OVAL trial enrollment resumes
06/15/21 Roth Capital
Roth does not see material change to VBL readout timelines
06/03/21 Roth Capital
Roth Capital ups VBL Therapeutics target to $7 on OVAL primary endpoint update
05/18/21 Guggenheim
VBL Therapeutics initiated with a Buy at Guggenheim
VTRS Viatris
$13.33 /

-0.24 (-1.77%)

06/15/21 Citi
Viatris initiated with a Neutral at Citi
04/06/21 RBC Capital
Viatris transferred with an Outperform at RBC Capital
03/25/21 Piper Sandler
Piper says Biogen Tecfidera patents could change thesis, but sees unknowns
03/12/21 Piper Sandler
Viatris price target lowered to $16 from $17 at Piper Sandler
NVS Novartis
$82.81 /

-0.68 (-0.81%)

09/20/21 Deutsche Bank
Novartis downgraded to Sell from Hold at Deutsche Bank
09/07/21 Wedbush
Wedbush downgrades Xoma to Neutral, cuts target to $22
07/28/21 JPMorgan
Novartis price target raised to CHF 84 from CHF 80 at JPMorgan

TODAY'S FREE FLY STORIES

Hot Stocks
Agnico Eagle, Kirkland Lake Gold shareholders approve merger » 13:39
11/27/21
11/27
13:39
11/27/21
13:39
AEM

Agnico Eagle

$51.24 /

-0.45 (-0.87%)

, KL

Kirkland Lake Gold

$40.28 /

-0.53 (-1.30%)

Agnico Eagle Mines (AEM)…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
KL Kirkland Lake Gold
$40.28 /

-0.53 (-1.30%)

AEM Agnico Eagle
$51.24 /

-0.45 (-0.87%)

AEM Agnico Eagle
$51.24 /

-0.45 (-0.87%)

11/10/21 National Bank
Agnico Eagle price target lowered to C$82 from C$83 at National Bank
10/12/21 Credit Suisse
Credit Suisse sees 're-rating potential' for gold valuation multiples
10/06/21
Fly Intel: Top five analyst upgrades
10/06/21 RBC Capital
Agnico Eagle upgraded to Outperform from Sector Perform at RBC Capital
KL Kirkland Lake Gold
$40.28 /

-0.53 (-1.30%)

11/22/21 National Bank
Kirkland Lake Gold price target raised to C$56 from C$55.50 at National Bank
11/02/21 Scotiabank
Kirkland Lake Gold price target lowered to C$52.25 from C$61 at Scotiabank
09/30/21 National Bank
Kirkland rating moved to Tender from Sector Perform at National Bank
09/29/21 Stifel
Agnico Eagle merger with Kirkland Lake builds on strengths, says Stifel
KL Kirkland Lake Gold
$40.28 /

-0.53 (-1.30%)

AEM Agnico Eagle
$51.24 /

-0.45 (-0.87%)

AEM Agnico Eagle
$51.24 /

-0.45 (-0.87%)

KL Kirkland Lake Gold
$40.28 /

-0.53 (-1.30%)

AEM Agnico Eagle
$51.24 /

-0.45 (-0.87%)

Periodicals
Gentherm a cheap way to play EV boom, Barron's says » 09:36
11/27/21
11/27
09:36
11/27/21
09:36
THRM

Gentherm

$83.98 /

-4.06 (-4.61%)

Gentherm, a small-cap…

Gentherm, a small-cap auto supplier, has 60% of the global market for heated and air-conditioned seats, towering over its next competitor at 10%, Daren Fonda writes in this week's edition of Barron's. Auto production is ailing due to a global semiconductor shortage. But the supply chain should ease up in the second half of 2022, giving Gentherm a sales lift, the author contends. Climate-controlled seating is expanding to the mass market-growing from 4% of U.S. new vehicles in 2013 to 18% in 2020. More important, Gentherm has a shot at the fastest-growing part of the car market, namely electric vehicles, the publication adds. Reference Link

ShowHide Related Items >><<
THRM Gentherm
$83.98 /

-4.06 (-4.61%)

THRM Gentherm
$83.98 /

-4.06 (-4.61%)

10/28/21 Roth Capital
Gentherm price target lowered to $85 from $92 at Roth Capital
10/27/21
Fly Intel: Top five analyst initiations
10/27/21 Seaport Global
Gentherm initiated with a Buy at Seaport Global
09/22/21
Fly Intel: Top five analyst initiations
THRM Gentherm
$83.98 /

-4.06 (-4.61%)

Periodicals
Nio, Xpeng, Li Auto look set to grow on bigger sales, Barron's says » 09:33
11/27/21
11/27
09:33
11/27/21
09:33
NIO

Nio

$39.88 /

-1.55 (-3.74%)

, XPEV

XPeng

$51.01 /

-3.43 (-6.30%)

, LI

Li Auto

$32.66 /

-0.005 (-0.02%)

Buying growth stocks when…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
XPEV XPeng
$51.01 /

-3.43 (-6.30%)

NIO Nio
$39.88 /

-1.55 (-3.74%)

LI Li Auto
$32.66 /

-0.005 (-0.02%)

NIO Nio
$39.88 /

-1.55 (-3.74%)

11/23/21 Citi
Citi says Nio shares oversold after offering, keeps $87 target
11/11/21 Mizuho
Nio price target lowered to $65 from $67 at Mizuho
11/11/21 Citi
Nio price target raised to $87 from $70 at Citi
11/04/21 Deutsche Bank
Nio price target raised to $70 from $60 at Deutsche Bank
XPEV XPeng
$51.01 /

-3.43 (-6.30%)

11/24/21 BofA
XPeng price target raised to $66 from $63 at BofA
11/24/21 Citi
XPeng price target raised to $92 from $87 at Citi
11/11/21 Citi
XPeng price target raised to $87 from $53.40 at Citi
10/28/21
Fly Intel: Top five analyst initiations
LI Li Auto
$32.66 /

-0.005 (-0.02%)

11/11/21 Citi
Li Auto price target raised to $200 from $165 at Citi
10/28/21 Bernstein
Bernstein starts Li Auto at Outperform, sees EVs as 'future' of Chinese autos
10/28/21 Bernstein
Li Auto initiated with an Outperform at Bernstein
XPEV XPeng
$51.01 /

-3.43 (-6.30%)

NIO Nio
$39.88 /

-1.55 (-3.74%)

LI Li Auto
$32.66 /

-0.005 (-0.02%)

  • 13
    Aug
  • 14
    Dec
  • 09
    Dec
  • 04
    Dec
XPEV XPeng
$51.01 /

-3.43 (-6.30%)

NIO Nio
$39.88 /

-1.55 (-3.74%)

XPEV XPeng
$51.01 /

-3.43 (-6.30%)

NIO Nio
$39.88 /

-1.55 (-3.74%)

LI Li Auto
$32.66 /

-0.005 (-0.02%)

XPEV XPeng
$51.01 /

-3.43 (-6.30%)

NIO Nio
$39.88 /

-1.55 (-3.74%)

LI Li Auto
$32.66 /

-0.005 (-0.02%)

Periodicals
IBM finally growing again, stock a big bargain, Barron's says » 09:27
11/27/21
11/27
09:27
11/27/21
09:27
IBM

IBM

$115.50 /

-1.21 (-1.04%)

, MSFT

Microsoft

$329.70 /

-8.13 (-2.41%)

Investors have…

Investors have understandably forsaken Big Blue, but it may be time to start paying attention to it again, Savitz writes in this week's edition of Barron's. IBM (IBM) is repairing its reputation with a new CEO who is making serious and lasting changes to its structure and ambitions, the author notes. For investors who missed Microsoft's (MSFT) turnaround, IBM could offer a second chance. Reference Link

ShowHide Related Items >><<
MSFT Microsoft
$329.70 /

-8.13 (-2.41%)

IBM IBM
$115.50 /

-1.21 (-1.04%)

IBM IBM
$115.50 /

-1.21 (-1.04%)

10/28/21 Credit Suisse
IBM assumed with an Outperform at Credit Suisse
10/21/21 Morgan Stanley
IBM's Q3 'a pause on the path to improving growth,' says Morgan Stanley
10/06/21 Evercore ISI
IBM removed from Tactical Outperform list at Evercore ISI
10/05/21 Credit Suisse
IBM price target raised to $176 from $167 at Credit Suisse
MSFT Microsoft
$329.70 /

-8.13 (-2.41%)

11/22/21 Wells Fargo
Wells Fargo starts Microsoft with Overweight, $400 target on 'bright future'
11/22/21 Wells Fargo
Microsoft initiated with an Overweight at Wells Fargo
11/19/21 UBS
Zoom Video price target lowered to $285 from $315 at UBS
11/16/21 Credit Suisse
Microsoft assumed with an Outperform at Credit Suisse
MSFT Microsoft
$329.70 /

-8.13 (-2.41%)

IBM IBM
$115.50 /

-1.21 (-1.04%)

MSFT Microsoft
$329.70 /

-8.13 (-2.41%)

IBM IBM
$115.50 /

-1.21 (-1.04%)

MSFT Microsoft
$329.70 /

-8.13 (-2.41%)

IBM IBM
$115.50 /

-1.21 (-1.04%)

MSFT Microsoft
$329.70 /

-8.13 (-2.41%)

IBM IBM
$115.50 /

-1.21 (-1.04%)

On The Fly
Opening Day: Aeroclean shares jump on first trading day » 09:17
11/27/21
11/27
09:17
11/27/21
09:17
AERC

Aeroclean

$81.55 /

+5.05 (+6.60%)

, RGF

The Real Good Food Company

$9.11 /

-0.15 (-1.62%)

, IOBT

IO Biotech

$7.82 /

+0.6 (+8.31%)

, MYNZ

Mainz Biomed

$9.80 /

-0.28 (-2.78%)

, CIAN

Cian

$14.90 /

-0.1 (-0.67%)

, NRDS

NerdWallet

$22.56 /

-0.18 (-0.79%)

, ARHS

Arhaus

$10.14 /

+0.075 (+0.75%)

, CDRE

Cadre

$19.40 /

-0.1 (-0.51%)

, EVO

Evotec SE

$23.91 /

+0.69 (+2.97%)

, MDXH

MDxHealth

$10.07 /

+0.86 (+9.34%)

, SOPA

Society Pass

$11.10 /

-1.96 (-15.01%)

, STRN

Stran & Company

$3.10 /

-0.13 (-4.02%)

, TCBX

Third Coast Bancshares

$27.57 /

-0.23 (-0.83%)

, NUVO

Nuvo Group

/

+

, AUST

Austin Gold

/

+

, CHO

Chobani

/

+

, CAST

FreeCast

/

+

, IOT

Samsara

/

+

, KETR

Keter

/

+

, QNIU

Qiniu

/

+

, BABA

Alibaba

$133.00 /

-3.62 (-2.65%)

, AUTH

Authentic Brands Group

$8.01 /

+ (+0.00%)

Shares of Aeroclean…

ShowHide Related Items >><<
STRN Stran & Company
$3.10 /

-0.13 (-4.02%)

IOT Samsara
/

+

CDRE Cadre
$19.40 /

-0.1 (-0.51%)

BABA Alibaba
$133.00 /

-3.62 (-2.65%)

AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

AERC Aeroclean
$81.55 /

+5.05 (+6.60%)

AERC Aeroclean
$81.55 /

+5.05 (+6.60%)

RGF The Real Good Food Company
$9.11 /

-0.15 (-1.62%)

IOBT IO Biotech
$7.82 /

+0.6 (+8.31%)

MYNZ Mainz Biomed
$9.80 /

-0.28 (-2.78%)

CIAN Cian
$14.90 /

-0.1 (-0.67%)

NRDS NerdWallet
$22.56 /

-0.18 (-0.79%)

ARHS Arhaus
$10.14 /

+0.075 (+0.75%)

CDRE Cadre
$19.40 /

-0.1 (-0.51%)

EVO Evotec SE
$23.91 /

+0.69 (+2.97%)

MDXH MDxHealth
$10.07 /

+0.86 (+9.34%)

SOPA Society Pass
$11.10 /

-1.96 (-15.01%)

STRN Stran & Company
$3.10 /

-0.13 (-4.02%)

TCBX Third Coast Bancshares
$27.57 /

-0.23 (-0.83%)

NUVO Nuvo Group
/

+

AUST Austin Gold
/

+

CHO Chobani
/

+

CAST FreeCast
/

+

IOT Samsara
/

+

KETR Keter
/

+

QNIU Qiniu
/

+

BABA Alibaba
$133.00 /

-3.62 (-2.65%)

11/24/21
Fly Intel: Top five analyst downgrades
11/24/21 Argus
Alibaba downgraded to Hold from Buy at Argus
11/23/21 Needham
Alibaba price target lowered to $230 from $330 at Needham
11/19/21 Benchmark
Alibaba price target lowered to $245 from $270 at Benchmark
AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

BABA Alibaba
$133.00 /

-3.62 (-2.65%)

  • 24
    Nov
  • 24
    Nov
  • 09
    Nov
  • 09
    Nov
  • 09
    Nov
  • 05
    Nov
  • 05
    Nov
  • 05
    Nov
  • 04
    Nov
  • 04
    Nov
  • 04
    Nov
  • 04
    Nov
  • 04
    Nov
  • 04
    Nov
BABA Alibaba
$133.00 /

-3.62 (-2.65%)

AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

STRN Stran & Company
$3.10 /

-0.13 (-4.02%)

RGF The Real Good Food Company
$9.11 /

-0.15 (-1.62%)

MDXH MDxHealth
$10.07 /

+0.86 (+9.34%)

KETR Keter
/

+

CHO Chobani
/

+

BABA Alibaba
$133.00 /

-3.62 (-2.65%)

NRDS NerdWallet
$22.56 /

-0.18 (-0.79%)

BABA Alibaba
$133.00 /

-3.62 (-2.65%)

General news
Fed's Bostic played down risks from the new Omicron variant » 17:40
11/26/21
11/26
17:40
11/26/21
17:40
$ECON

Economic Data

/

+

Fed's Bostic played…

Fed's Bostic played down risks from the new Omicron variant and its impact on the economy in a Fox New interview. Though there could be some slowing in overall activity, he doubted it would be as much as with Delta. He noted there is a lot of momentum in the economy and added it is certainly possible the FOMC could hike rates twice in 2022, stressing the Fed is not going to let inflation get out of control. He remains "very open" to speeding up the pace of the slowing in asset purchases. He sees late Q1 or early Q2 as a possible timeframe for ending purchases. Bostic is a voter this year and was on the dovish side of the spectrum until the last few months as inflation remained elevated.

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

General news
Treasury Market Summary » 17:30
11/26/21
11/26
17:30
11/26/21
17:30
$ECON

Economic Data

/

+

Treasury Market Summary:…

Treasury Market Summary: it was the best of days and the worst of days in over a year for Treasuries and equities, respectively. Indeed "Black Friday" took on a new connotation as Wall Street took an ominous spin lower on fears over the new covid strain, Omicron. Stocks plunged and all of the major indexes posted declines of better than -2.2% as reopening and reflation trades were crushed. It was the largest one-day drop for the Dow since October 2020. But, that saw cash surge back into the safety of bonds with yields dropping dramatically, taking the 10-year rate back south of the 1.50% mark. It was the largest single day decline in the yield since March 2020 when covid first hit the markets. Fears over an aggressive shift from the FOMC to a more hawkish stance were slashed too. Expectations the Fed could speed up its pace of tapering as soon as the December 14-15 meeting due to the pick up in inflation weighed heavily on the money markets and bonds earlier this week. But they were sharply undone today with rate liftoff pushed back to September 2022, from June (and even May). It was a shortened session after the Thanksgiving holiday, but volume was solid.

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

General news
Week of 11/24 Fed balance sheet reserve bank credit $24.8B  16:34
11/26/21
11/26
16:34
11/26/21
16:34
$ECON

Economic Data

/

+

 
ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

General news
Week of 11/24 Fed balance sheet total assets $6.8B  16:34
11/26/21
11/26
16:34
11/26/21
16:34
$ECON

Economic Data

/

+

 
ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

General news
Week of 11/24 Fed balance sheet level $8.682T  16:34
11/26/21
11/26
16:34
11/26/21
16:34
$ECON

Economic Data

/

+

 
ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

Technical Analysis
NASDAQ market internals summary » 16:23
11/26/21
11/26
16:23
11/26/21
16:23
$NSD

NASDAQ Market Internals

/

+

Volume is above average…

Volume is above average for this time of day. Breadth is bearish across the board. Advancing Issues: 919 / Declining Issues: 3632 -- for a ratio of 0.3 to 1. Advancing Volume: 1,006,406,000 / Declining Volume: 2,433,493,000 -- for a ratio of 0.4 to 1. New 52-Week Highs: 35 / New 52-Week Lows: 349.

ShowHide Related Items >><<
$NSD NASDAQ Market Internals
/

+

Technical Analysis
NYSE market internals summary » 16:22
11/26/21
11/26
16:22
11/26/21
16:22
$NYE

NYSE Market Internals

/

+

Volume is above average…

Volume is above average for this time of day. Breadth is bearish across the board. Advancing Issues: 469 / Declining Issues: 2860 -- for a ratio of 0.2 to 1. Advancing Volume: 346,472,000 / Declining Volume: 3,140,522,000 -- for a ratio of 0.1 to 1. New 52-Week Highs: 21 / New 52-Week Lows: 210.

ShowHide Related Items >><<
$NYE NYSE Market Internals
/

+

Conference/Events
UBS technology analysts to hold an analyst/industry conference call » 16:13
11/26/21
11/26
16:13
11/26/21
16:13
SNOW

Snowflake

$361.94 /

+6.655 (+1.87%)

, CRWD

Crowdstrike

$233.73 /

+2.93 (+1.27%)

, SPLK

Splunk

$125.25 /

+0.2 (+0.16%)

, VEEV

Veeva

$288.19 /

-2.64 (-0.91%)

Technology Analysts…

Technology Analysts Keirstead & Rocha provide a recap of Snowflake, Crowdstrike, Splunk and Veeva reported earnings on an Analyst/Industry conference call to be held on December 2 at 8:30 am.

ShowHide Related Items >><<
VEEV Veeva
$288.19 /

-2.64 (-0.91%)

SPLK Splunk
$125.25 /

+0.2 (+0.16%)

SNOW Snowflake
$361.94 /

+6.655 (+1.87%)

CRWD Crowdstrike
$233.73 /

+2.93 (+1.27%)

SNOW Snowflake
$361.94 /

+6.655 (+1.87%)

11/19/21
Fly Intel: Top five analyst downgrades
11/19/21 Rosenblatt
Snowflake downgraded to Neutral on valuation at Rosenblatt
11/19/21 Rosenblatt
Snowflake downgraded to Neutral from Buy at Rosenblatt
11/16/21 Credit Suisse
Snowflake initiated with an Outperform at Credit Suisse
CRWD Crowdstrike
$233.73 /

+2.93 (+1.27%)

11/24/21 Deutsche Bank
Crowdstrike price target lowered to $300 from $320 at Deutsche Bank
11/18/21
Fly Intel: Top five analyst initiations
11/18/21 DA Davidson
Crowdstrike initiated with a Buy at DA Davidson
11/15/21
Fly Intel: Top five analyst initiations
SPLK Splunk
$125.25 /

+0.2 (+0.16%)

11/17/21 Argus
Argus 'surprised' by Splunk's 'abrupt' CEO dismissal
11/16/21 Mizuho
Splunk price target lowered to $165 from $175 at Mizuho
11/16/21 Credit Suisse
Splunk initiated with an Outperform at Credit Suisse
11/16/21 Deutsche Bank
Splunk price target lowered to $155 from $180 at Deutsche Bank
VEEV Veeva
$288.19 /

-2.64 (-0.91%)

10/01/21 Stifel
Veeva assumed with a Buy at Stifel
09/03/21 SVB Leerink
Veeva price target raised to $296 from $294 at SVB Leerink
09/02/21 UBS
Veeva price target raised to $320 from $270 at UBS
09/02/21 Baird
Veeva price target raised to $349 from $340 at Baird
VEEV Veeva
$288.19 /

-2.64 (-0.91%)

SPLK Splunk
$125.25 /

+0.2 (+0.16%)

SNOW Snowflake
$361.94 /

+6.655 (+1.87%)

CRWD Crowdstrike
$233.73 /

+2.93 (+1.27%)

  • 16
    Mar
CRWD Crowdstrike
$233.73 /

+2.93 (+1.27%)

VEEV Veeva
$288.19 /

-2.64 (-0.91%)

SPLK Splunk
$125.25 /

+0.2 (+0.16%)

SNOW Snowflake
$361.94 /

+6.655 (+1.87%)

CRWD Crowdstrike
$233.73 /

+2.93 (+1.27%)

SPLK Splunk
$125.25 /

+0.2 (+0.16%)

SNOW Snowflake
$361.94 /

+6.655 (+1.87%)

CRWD Crowdstrike
$233.73 /

+2.93 (+1.27%)

Conference/Events
UBS technology analysts to hold an analyst/industry conference call » 16:08
11/26/21
11/26
16:08
11/26/21
16:08
CRM

Salesforce

$283.00 /

-6.155 (-2.13%)

, ZS

Zscaler

$337.00 /

-5.25 (-1.53%)

Technology Analysts…

Technology Analysts provide a recap of salesforce.com and Zscaler reported earnings on an Analyst/Industry conference call to be held on December 1 at 8:30 am.

ShowHide Related Items >><<
ZS Zscaler
$337.00 /

-5.25 (-1.53%)

CRM Salesforce
$283.00 /

-6.155 (-2.13%)

CRM Salesforce
$283.00 /

-6.155 (-2.13%)

11/23/21 BofA
Salesforce price target raised to $360 from $330 at BofA
11/23/21 Jefferies
Salesforce price target raised to $360 from $325 at Jefferies
11/23/21 Citi
Salesforce price target raised to $308 from $280 at Citi
11/22/21 Atlantic Equities
Atlantic Equities assumes 'low-risk' Salesforce at Overweight
ZS Zscaler
$337.00 /

-5.25 (-1.53%)

11/24/21 Deutsche Bank
Zscaler price target raised to $400 from $325 at Deutsche Bank
11/16/21 Credit Suisse
Zscaler initiated with an Outperform at Credit Suisse
11/15/21 Mizuho
Zscaler price target raised to $385 from $320 at Mizuho
11/09/21 BTIG
Zscaler price target raised to $401 from $324 at BTIG
ZS Zscaler
$337.00 /

-5.25 (-1.53%)

CRM Salesforce
$283.00 /

-6.155 (-2.13%)

ZS Zscaler
$337.00 /

-5.25 (-1.53%)

CRM Salesforce
$283.00 /

-6.155 (-2.13%)

ZS Zscaler
$337.00 /

-5.25 (-1.53%)

CRM Salesforce
$283.00 /

-6.155 (-2.13%)

ZS Zscaler
$337.00 /

-5.25 (-1.53%)

CRM Salesforce
$283.00 /

-6.155 (-2.13%)

Hot Stocks
Moderna testing existing and new variant-specific vaccine candidates for Omicron » 15:37
11/26/21
11/26
15:37
11/26/21
15:37
MRNA

Moderna

$331.10 /

+57.83 (+21.16%)

Moderna announced updates…

Moderna announced updates to its strategy to address SARS-CoV-2 variants of concern, given the emergence of the B.1.1.529, or "Omicron," variant. "The recently described Omicron variant includes mutations seen in the Delta variant that are believed to increase transmissibility and mutations seen in the Beta and Delta variants that are believed to promote immune escape. The combination of mutations represents a significant potential risk to accelerate the waning of natural and vaccine-induced immunity. A booster dose of an authorized vaccine represents the only currently available strategy for boosting waning immunity. The Moderna COVID-19 vaccine - mRNA-1273 - is authorized as a booster for many populations at the 50 microgram dose level. The Company is working rapidly to test the ability of the current vaccine dose to neutralize the Omicron variant and data is expected in the coming weeks. Since early 2021, Moderna has advanced a comprehensive strategy to anticipate new variants of concern. This strategy includes three levels of response should the currently authorized 50 microgram booster dose of mRNA-1273 prove insufficient to boost waning immunity against the Omicron variant," the company stated. Moderna said it has already tested a higher dose booster of mRNA-1273, 100 microgram, in healthy adults. Moderna has completed dosing of 306 participants in a safety and immunogenicity study of this high dose booster. The 100 microgram dose of mRNA-1273 has also recently been studied by the National Institutes of Health in the U.S. and has generally resulted in the highest neutralizing titers against prior SARS-CoV-2 strains. Moderna is working to rapidly test sera from its high dose booster recipients in neutralizing assays to determine if the 100 microgram dose provides superior neutralizing protection against Omicron. Second, Moderna is already studying two multi-valent booster candidates in the clinic that were designed to anticipate mutations such as those that have emerged in the Omicron variant. The first candidate, mRNA-1273.211, includes several mutations present in the Omicron variant that were also present in the Beta variant of concern. The company has completed dosing in a potentially pivotal safety and immunogenicity study of mRNA-1273.211 at the 50 microgram and 100 microgram dose levels. A second multi-valent candidate, mRNA-1273.213, includes many of the mutations present in the Omicron variant that were also present in the Beta and Delta variants. The company has completed dosing at the 100 microgram dose level and also plans to explore the 50 microgram dose level in approximately 584 participants. Moderna will rapidly expand testing of sera from completed and ongoing multi-valent booster studies to determine if these multi-valent candidates are able to provide superior neutralizing protection against Omicron. Third, Moderna will rapidly advance an Omicron-specific booster candidate, mRNA-1273.529. This candidate is part of the company's strategy to advance variant-specific candidates for a subset of variants of significant concern. During 2021 this has already included Beta- and Delta-specific boosters. The company has repeatedly demonstrated the ability to advance new candidates to clinical testing in 60-90 days. "From the beginning, we have said that as we seek to defeat the pandemic, it is imperative that we are proactive as the virus evolves. The mutations in the Omicron variant are concerning and for several days, we have been moving as fast as possible to execute our strategy to address this variant. We have three lines of defense that we are advancing in parallel: we have already evaluated a higher dose booster of mRNA-1273, second, we are already studying two multi-valent booster candidates in the clinic that were designed to anticipate mutations such as those that have emerged in the Omicron variant and data is expected in the coming weeks, and third, we are rapidly advancing a Omicron-specific booster candidate," said Stephane Bancel, CEO of Moderna.

ShowHide Related Items >><<
MRNA Moderna
$331.10 /

+57.83 (+21.16%)

MRNA Moderna
$331.10 /

+57.83 (+21.16%)

11/26/21 Piper Sandler
Moderna has been preparing for emergence of new variants, says Piper Sandler
11/23/21 Morgan Stanley
Positive flu vaccine data can drive Moderna 10%-20% higher, says Morgan Stanley
11/19/21 Piper Sandler
Moderna can gain share from Pfizer in booster market, says Piper Sandler
11/12/21 Piper Sandler
Piper keeps $348 target on Moderna after solid tumor data
MRNA Moderna
$331.10 /

+57.83 (+21.16%)

MRNA Moderna
$331.10 /

+57.83 (+21.16%)

MRNA Moderna
$331.10 /

+57.83 (+21.16%)

MRNA Moderna
$331.10 /

+57.83 (+21.16%)

Conference/Events
UBS biotechnology analysts to hold an analyst/industry conference call » 15:29
11/26/21
11/26
15:29
11/26/21
15:29

Biotech Analysts Merle…

Biotech Analysts Merle & Rajavelu provide perspectives on the upcoming Phase 3 Data readouts for ATTR-CM (Transthyretin Amyloid Cardiomyopathy) data readouts on an Analyst/Industry conference call to be held on November 30 at 10 am.

Technical Analysis
NASDAQ market internals summary » 15:23
11/26/21
11/26
15:23
11/26/21
15:23
$NSD

NASDAQ Market Internals

/

+

Volume is above average…

Volume is above average for this time of day. Breadth is bearish across the board. Advancing Issues: 919 / Declining Issues: 3632 -- for a ratio of 0.3 to 1. Advancing Volume: 1,002,836,000 / Declining Volume: 2,418,765,000 -- for a ratio of 0.4 to 1. New 52-Week Highs: 35 / New 52-Week Lows: 349.

ShowHide Related Items >><<
$NSD NASDAQ Market Internals
/

+

Technical Analysis
NYSE market internals summary » 15:22
11/26/21
11/26
15:22
11/26/21
15:22
$NYE

NYSE Market Internals

/

+

Volume is above average…

Volume is above average for this time of day. Breadth is bearish across the board. Advancing Issues: 469 / Declining Issues: 2860 -- for a ratio of 0.2 to 1. Advancing Volume: 344,464,000 / Declining Volume: 3,113,466,000 -- for a ratio of 0.1 to 1. New 52-Week Highs: 21 / New 52-Week Lows: 210.

ShowHide Related Items >><<
$NYE NYSE Market Internals
/

+

Conference/Events
UBS technology analysts to hold an analyst/industry conference call » 15:20
11/26/21
11/26
15:20
11/26/21
15:20

Technology Analysts…

Technology Analysts Keirstead and Rocha provide an update on the Technology sector on an Analyst/Industry conference call to be held on November 30 at 9 am.

Conference/Events
UBS restaurants analyst to hold analyst/industry conference call » 15:15
11/26/21
11/26
15:15
11/26/21
15:15

Restaurants Analyst…

Restaurants Analyst Geiger, along with a quick serve restaurant coffee franchisee, discuss the industry on an Analyst/Industry conference call to be held on November 29 at 11 am.

Conference/Events
UBS consumer goods analyst to hold analyst/industry conference call » 15:12
11/26/21
11/26
15:12
11/26/21
15:12

Consumer Goods Analyst…

Consumer Goods Analyst Sole provides a recap of the Black Friday Weekend on an Analyst/Industry conference call to be held on November 29 at 10 am.

Conference/Events
Cowen pharma/biotech analysts to hold an analyst/industry conference call » 15:03
11/26/21
11/26
15:03
11/26/21
15:03

Pharmaceuticals Analyst…

Pharmaceuticals Analyst Scala and Biotech Analyst Rodriguez-Dumont discuss the current status and future opportunities for women's health on an Analyst/Industry conference call to be held on December 3 at 10 am.

Conference/Events
Cowen financial services analyst to hold analyst/industry conference call » 14:59
11/26/21
11/26
14:59
11/26/21
14:59

Head of Equity…

Head of Equity Derivatives Forman and Financial Services Analyst Seiberg discuss Cryptocurrency and Digital Assets with a look back at 2021 and thoughts for 2022 on an Analyst/Industry conference call to be held on December 2 at 11 am.

Conference/Events
Cowen media & entertainment analyst to hold analyst/industry conference call » 14:54
11/26/21
11/26
14:54
11/26/21
14:54
DISCA

Discovery

$24.72 /

-0.47 (-1.87%)

Media & Entertainment…

Media & Entertainment Analyst Creutz and TMT Policy Analyst Gallant discusses the Discovery-Time Warner merger-spin including the fundamental value, regulatory risk and when-issued market on an Analyst/Industry conference call to be held on December 2 at 11 am.

ShowHide Related Items >><<
DISCA Discovery
$24.72 /

-0.47 (-1.87%)

DISCA Discovery
$24.72 /

-0.47 (-1.87%)

11/08/21 Macquarie
Macquarie upgrades Discovery to Outperform, raises target to $40
11/08/21 Macquarie
Discovery upgraded to Outperform from Neutral at Macquarie
11/01/21 Bernstein
Bernstein upgrades Discovery to Market Perform, lowers target to $26
11/01/21 Bernstein
Discovery upgraded to Market Perform from Underperform at Bernstein
DISCA Discovery
$24.72 /

-0.47 (-1.87%)

  • 14
    Apr
DISCA Discovery
$24.72 /

-0.47 (-1.87%)

DISCA Discovery
$24.72 /

-0.47 (-1.87%)

DISCA Discovery
$24.72 /

-0.47 (-1.87%)

Conference/Events
Cowen ESG & restaurant analysts hold analyst/industry conference call » 14:47
11/26/21
11/26
14:47
11/26/21
14:47

ESG Policy Analyst Miller…

ESG Policy Analyst Miller and Restaurant Analyst Charles discuss how today shapes tomorrow and focus on the Restaurant Industry's ESG framework on an Analyst/Industry conference call to be held on December 1 at 11 am.

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.